These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 35234695)
1. Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study. Jin D; Jin K; Chen B; Zhou X; Yuan Q; Zhang Z; Wei Q; Qiu S Chin Med J (Engl); 2022 Apr; 135(7):820-827. PubMed ID: 35234695 [TBL] [Abstract][Full Text] [Related]
2. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728 [TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study. Yi Z; Li H; Li M; Hu J; Cai Z; Liu Z; Zhang C; Cheng C; He Y; Chen J; Zu X; Wang R World J Urol; 2024 Oct; 42(1):581. PubMed ID: 39419868 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443 [TBL] [Abstract][Full Text] [Related]
6. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176 [TBL] [Abstract][Full Text] [Related]
7. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study. Castelli T; Russo GI; Favilla V; Urzi D; Spitaleri F; Reale G; Giardina R; Saita A; Madonia M; Cimino S; Morgia G Int Braz J Urol; 2014; 40(3):322-9. PubMed ID: 25010298 [TBL] [Abstract][Full Text] [Related]
8. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390 [TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy. Chen H; Qu M; Shi H; Dong Z; Wang Y; Gao X J Cancer Res Clin Oncol; 2023 Jul; 149(8):4925-4932. PubMed ID: 36308526 [TBL] [Abstract][Full Text] [Related]
12. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083 [TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
14. Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance? Niklas C; Saar M; Nini A; Linxweiler J; Siemer S; Junker K; Stoeckle M World J Urol; 2021 Sep; 39(9):3231-3237. PubMed ID: 33502558 [TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy. Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085 [TBL] [Abstract][Full Text] [Related]
17. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983 [TBL] [Abstract][Full Text] [Related]
18. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845 [TBL] [Abstract][Full Text] [Related]
20. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis. Si S; Zheng B; Wang Z; Niu Z Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]